SG11202009735QA - Bcl6 inhibitors - Google Patents
Bcl6 inhibitorsInfo
- Publication number
- SG11202009735QA SG11202009735QA SG11202009735QA SG11202009735QA SG11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl6 inhibitors
- bcl6
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
PCT/GB2019/051058 WO2019197842A1 (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009735QA true SG11202009735QA (en) | 2020-10-29 |
Family
ID=66240166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009735QA SG11202009735QA (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Country Status (16)
Country | Link |
---|---|
US (2) | US11512095B2 (pt) |
EP (2) | EP3774817B1 (pt) |
JP (2) | JP7493454B2 (pt) |
KR (1) | KR20200144109A (pt) |
CN (1) | CN112334475A (pt) |
AU (2) | AU2019253510B2 (pt) |
BR (1) | BR112020020832A2 (pt) |
CA (1) | CA3095371A1 (pt) |
DK (1) | DK3774817T3 (pt) |
ES (1) | ES2939776T3 (pt) |
HR (1) | HRP20230120T1 (pt) |
IL (2) | IL296734A (pt) |
MX (2) | MX2020010805A (pt) |
PT (1) | PT3774817T (pt) |
SG (1) | SG11202009735QA (pt) |
WO (1) | WO2019197842A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL296734A (en) * | 2018-04-13 | 2022-11-01 | The Institute Of Cancer Res Royal Cancer Hospital | bcl6 inhibitors |
GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
KR20220102156A (ko) * | 2019-10-17 | 2022-07-19 | 아비나스 오퍼레이션스, 인코포레이티드 | Bcl6 표적화 모이어티에 연결된 e3 유비퀴틴 리가아제 결합 모이어티를 함유하는 이기능성 분자 |
CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
US20240287091A1 (en) | 2022-06-06 | 2024-08-29 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
TW202415655A (zh) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | 1,8—萘啶—2—酮異雙功能bcl6降解劑 |
WO2024019995A1 (en) * | 2022-07-19 | 2024-01-25 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
IL153325A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
WO2010056038A2 (ko) * | 2008-11-11 | 2010-05-20 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
KR101763504B1 (ko) | 2013-03-05 | 2017-07-31 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
WO2014204859A2 (en) | 2013-06-17 | 2014-12-24 | Melnick Ari | Bcl6 inhibitors as anticancer agents |
WO2018108704A1 (en) * | 2016-12-13 | 2018-06-21 | Boehringer Ingelheim International Gmbh | New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors |
EP3630749B9 (en) * | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
IL270869B2 (en) | 2017-05-26 | 2023-09-01 | Cancer Research Tech Ltd | Benzimidazolone derivative inhibitors of bcl6 |
IL296734A (en) * | 2018-04-13 | 2022-11-01 | The Institute Of Cancer Res Royal Cancer Hospital | bcl6 inhibitors |
-
2019
- 2019-04-12 IL IL296734A patent/IL296734A/en unknown
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 KR KR1020207032149A patent/KR20200144109A/ko not_active Application Discontinuation
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt unknown
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 EP EP22211485.2A patent/EP4201939A1/en active Pending
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en active Application Filing
- 2019-04-12 CN CN201980039513.4A patent/CN112334475A/zh active Pending
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US20230287003A1/en active Pending
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501A1/en active Pending
-
2024
- 2024-05-21 JP JP2024082277A patent/JP2024119835A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2939776T3 (es) | 2023-04-26 |
IL277778B2 (en) | 2023-03-01 |
BR112020020832A2 (pt) | 2021-01-19 |
MX2020010805A (es) | 2021-01-29 |
JP2021521165A (ja) | 2021-08-26 |
JP2024119835A (ja) | 2024-09-03 |
HRP20230120T1 (hr) | 2023-06-09 |
US11512095B2 (en) | 2022-11-29 |
AU2019253510A1 (en) | 2020-10-22 |
CA3095371A1 (en) | 2019-10-17 |
IL277778B (en) | 2022-11-01 |
CN112334475A (zh) | 2021-02-05 |
EP4201939A1 (en) | 2023-06-28 |
PT3774817T (pt) | 2023-03-09 |
DK3774817T3 (da) | 2023-02-13 |
EP3774817B1 (en) | 2022-12-07 |
AU2019253510B2 (en) | 2023-08-10 |
EP3774817A1 (en) | 2021-02-17 |
US20230287003A1 (en) | 2023-09-14 |
AU2023263501A1 (en) | 2023-11-30 |
IL277778A (en) | 2020-11-30 |
KR20200144109A (ko) | 2020-12-28 |
JP7493454B2 (ja) | 2024-05-31 |
MX2023004920A (es) | 2023-05-16 |
IL296734A (en) | 2022-11-01 |
US20210163497A1 (en) | 2021-06-03 |
WO2019197842A1 (en) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283639A (en) | kif18a inhibitors | |
IL292642A (en) | ras inhibitors | |
IL292643A (en) | ras inhibitors | |
IL292644A (en) | ras inhibitors | |
SG11202009933WA (en) | Bcl-2 INHIBITORS | |
IL269196A (en) | New inhibitors | |
IL277778B (en) | inhibitors of bcl6 | |
IL276813A (en) | Arginase inhibitors | |
GB201705971D0 (en) | Inhibitor compounds | |
EP3817736A4 (en) | PIKFYVE INHIBITORS | |
ZA201907136B (en) | Ip6k inhibitors | |
GB201819126D0 (en) | Inhibitor compounds | |
IL276013A (en) | pi4kiiibeta inhibitors | |
ZA201808552B (en) | Novel b-lactamase inhibitors | |
EP3600301A4 (en) | KDM4 INHIBITORS | |
IL283309A (en) | rip1 inhibitors | |
IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
IL277806A (en) | Growth inhibitor | |
IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
IL283112A (en) | Lox inhibitors | |
GB201809295D0 (en) | Lox inhibitors | |
GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
GB201905476D0 (en) | MAPA4K4 Inhibitors | |
GB201812462D0 (en) | Inhibitors | |
GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |